Page 86 - 《中国药房》2023年24期
P. 86

糖尿病患者DRG分组效果及住院费用影响因素分析                                                          Δ



                 1 *
                                           2
                                   1
                                                   1 #
          聂晓静 ,付豪斐 ,白荷荷 ,李亚萍 ,王金萍 (1.西安市中心医院药剂科,西安 710003;2.西安市中心医院质
                           2
          控科,西安 710003)
          中图分类号  R95      文献标志码  A      文章编号  1001-0408(2023)24-3020-05
          DOI  10.6039/j.issn.1001-0408.2023.24.11

          摘   要  目的  探讨糖尿病疾病诊断相关分组(DRG)的分组效果及住院费用控制的影响因素,为完善 DRG 付费体系、降低医疗
          费用、提高医保基金使用效能提供依据。方法  回顾性分析2021年1月1日至2023年6月30日西安市某三级甲等医院住院治疗
          的 4 368 例糖尿病患者的病案信息,汇总其 DRG 分组情况,采用单因素方差分析和 Bonferroni 多重比较分析不同 DRG 分组患者
          的住院费用,采用变异系数(CV)评价组内异质性,采用单因素线性回归分析和多元线性回归分析探讨影响住院费用的因素。
          结果与结论  4个DRG组患者住院费用的CV值均小于0.8,分组结果较好且组内一致性较好;4组患者住院费用比较差异有统计
          学意义,且国家医疗保障局DRG1.1版FW11组患者的住院费用显著高于其他3组(P<0.05)。住院天数、药品费用、其他诊断数
          量、检验费用和付款方式对糖尿病患者的住院费用有显著正向影响;是否有药师干预对患者的住院费用有显著负向影响。在
          DRG支付方式下,医疗机构可考虑多学科联动,纳入包括药师干预在内的多种管理和服务工具,制定精细化管理措施,从而降低
          患者家庭和社会的经济负担。
          关键词  疾病诊断相关分组;糖尿病;住院费用;影响因素


          Analysis of DRG grouping effect and influential factors of hospitalization cost of diabetic patients
                                                        2
                                                                        1
                                             1
          NIE Xiaojing ,FU Haofei ,BAI Hehe ,LI Yaping ,WANG Jinping(1.  Dept.  of  Pharmacy,  Xi’an  Central
                      1
                                  2
          Hospital, Xi’an 710003, China;2. Dept. of Quality Control, Xi’an Central Hospital, Xi’an 710003, China)
          ABSTRACT    OBJECTIVE  To  explore  the  grouping  efficacy  of  diagnosis  related  group (DRG)  and  the  influential  factors  of
          hospitalization cost in diabetes cases, and to provide theoretical support for improving DRG payment system, reducing medical cost
          and  enhancing  the  efficiency  of  medical  insurance  funds.  METHODS  The  information  of  4  368  diabetic  patients  who  were
          hospitalized in a 3A hospital in Xi’an from January 1, 2021 to June 30, 2023 was retrospectively analyzed, and DRG grouping of
          them was summarized; the hospitalization costs of patients in different DRG groups were analyzed by using one way ANOVA and
          Bonferroni multiple comparison. Coefficient of variation (CV) was used for evaluation within the group, and the influential factors
          of  hospitalization  costs  were  analyzed  by  one-way  linear  regression  analysis  and  multi-factor  linear  regression  analysis.  RESULTS
          &  CONCLUSIONS  The  CV  values  of  the  four  DRG  groups  were  all  lower  than  0.8,  indicating  good  grouping  results  and  good
          consistency  within  the  group;  the  difference  of  hospitalization  cost  among  the  four  groups  was  statistically  significant (P<0.05),
          and the hospitalization cost of China Healthcare Security-DRG version 1.1 FW11 group was significantly higher than those of other
          three groups (P<0.05). Length of stay, drug cost, the number of other diagnoses, test cost and payment method have significant
          positive  effects  on  the  hospitalization  cost  of  diabetic  patients.  Whether  there  is  pharmacist  intervention  has  a  significant  negative
          influence  on  the  hospitalization  cost  of  patients.  Under  the  DRG  payment  method,  medical  institutions  can  consider
          multidisciplinary  linkage  and  incorporate  a  variety  of  management  and  service  tools,  including  pharmacist’s  intervention,  to
          develop refined management measures, to reduce the economic burden of patients’ families and society.
          KEYWORDS     diagnosis related group; diabetes; hospitalization cost; influential factors


              国际糖尿病联盟(International Diabetes Federation,      者,成人患病率约为 10.5%;其中,中国是糖尿病患者人
          IDF)发布的数据显示,2021 年全球有 5.37 亿糖尿病患                    数最多的国家,约有1.4亿患者 。糖尿病导致的过早死
                                                                                        [1]
                                                              亡和残疾,给患者家庭及社会带来了沉重的经济负担。
              Δ  基金项目 西 安 市 卫 生 健 康 委 员 会 面 上 培 育 项 目(No.
          2023ms01)                                           据 IDF 统计,2021 年,糖尿病造成的全球卫生支出约
             *第一作者 副主任药师,硕士。研究方向:药学服务、慢病患者治                   9 660亿美元,占全球健康支出的9% 。
                                                                                            [1]
          疗药物管理。E-mail:niexiaojingwell@163.com
                                                                  疾病诊断相关分组(diagnosis related group,DRG)
              # 通信作者 副主任药师,硕士。研究方向:临床药学。E-mail:
          343369342@qq.com                                    是国际公认的较先进的医保支付方式之一,在控制医疗


          · 3020 ·    China Pharmacy  2023 Vol. 34  No. 24                            中国药房  2023年第34卷第24期
   81   82   83   84   85   86   87   88   89   90   91